These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 7506061)
21. [Hematopoietic growth factors in prophylaxis and therapy of infections complications in children with neutropenia]. Lehrnbecher T Klin Padiatr; 2001; 213(4):212-38. PubMed ID: 11528556 [TBL] [Abstract][Full Text] [Related]
22. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients. Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163 [TBL] [Abstract][Full Text] [Related]
24. Cytokines in tumor therapy (GM-CSF, G-CSF, and IL-3). Proceedings of the satellite symposium to the 15th UICC Congress. Hamburg, Federal Republic of Germany, August 18, 1990. Am J Clin Oncol; 1991; 14 Suppl 1():S1-63. PubMed ID: 1710873 [No Abstract] [Full Text] [Related]
25. Treatment of acute myeloid leukemia with cytokines: effect on duration of neutropenia and response to infections. Rowe JM Clin Infect Dis; 1998 Jun; 26(6):1290-4. PubMed ID: 9636848 [TBL] [Abstract][Full Text] [Related]
26. Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy. Herbst C; Naumann F; Kruse EB; Monsef I; Bohlius J; Schulz H; Engert A Cochrane Database Syst Rev; 2009 Jan; (1):CD007107. PubMed ID: 19160320 [TBL] [Abstract][Full Text] [Related]
27. Lack of benefit of granulocyte macrophage or granulocyte colony stimulating factor in patients with febrile neutropenia. Siddiqui T; Burney IA; Kakepoto GN; Khurshid M; Salam A; Smego RA J Pak Med Assoc; 2002 May; 52(5):206-10. PubMed ID: 12174492 [TBL] [Abstract][Full Text] [Related]
28. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Berghmans T; Paesmans M; Lafitte JJ; Mascaux C; Meert AP; Jacquy C; Burniat A; Steels E; Vallot F; Sculier JP Support Care Cancer; 2002 Apr; 10(3):181-8. PubMed ID: 11904782 [TBL] [Abstract][Full Text] [Related]
29. Differential immunostimulating effect of granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF) and interferon gamma (IFNgamma) after severe trauma. Lendemans S; Kreuzfelder E; Waydhas C; Schade FU; Flohé S Inflamm Res; 2007 Jan; 56(1):38-44. PubMed ID: 17334669 [TBL] [Abstract][Full Text] [Related]
30. [Clinical application of hematopoietic growth factor (IL-3, G-CSF, GM-CSF, and EPO)]. Motoyoshi K Nihon Rinsho; 1992 Aug; 50(8):1967-72. PubMed ID: 1279240 [TBL] [Abstract][Full Text] [Related]
31. Use of cytokines in the treatment of acute lymphoblastic leukemia. Nemunaitis J Leukemia; 1997 May; 11 Suppl 4():S36-7. PubMed ID: 9179281 [TBL] [Abstract][Full Text] [Related]
32. [Hematopoietic growth factors in prevention and therapy of infectious complications in premature and newborn infants]. Lehrnbecher T Z Geburtshilfe Neonatol; 2001; 205(5):167-73. PubMed ID: 11727663 [TBL] [Abstract][Full Text] [Related]
33. Colony-stimulating factors for the management of neutropenia in cancer patients. Dale DC Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591 [TBL] [Abstract][Full Text] [Related]
34. Increased levels of multiple forms of dihydrofolate reductase in peripheral blood leucocytes of cancer patients receiving haematopoietic colony-stimulating factors: interim analysis. Iqbal MP; Burney IA; Sultana F; Mehboobali N; Siddiqui T Exp Mol Med; 2000 Jun; 32(2):84-7. PubMed ID: 10926120 [TBL] [Abstract][Full Text] [Related]
35. [Low-dose granulocyte colony-stimulating factor combined with granulocyte-macrophage colony-stimulating factor for mobilizing peripheral CD34+ hematopoietic progenitor cells]. Meng FY; Xu B; Sun J; Yang Y; Niu JN Di Yi Jun Yi Da Xue Xue Bao; 2004 Sep; 24(9):1051-2. PubMed ID: 15447861 [TBL] [Abstract][Full Text] [Related]
36. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Bohlius J; Reiser M; Schwarzer G; Engert A Cochrane Database Syst Rev; 2004; (3):CD003189. PubMed ID: 15266474 [TBL] [Abstract][Full Text] [Related]
37. [Clinical use of granulocyte colony stimulating-factors (GM-CSF and G-CSF]. Borota R; Borota J; Belić A; Gebauer E; Stefanović N Med Pregl; 1997; 50(3-4):87-93. PubMed ID: 9229690 [TBL] [Abstract][Full Text] [Related]
38. Hematopoietic management in oncology practice. Part 1. Myeloid growth factors. Glaspy JA Oncology (Williston Park); 2003 Nov; 17(11):1593-603. PubMed ID: 14682110 [TBL] [Abstract][Full Text] [Related]
39. Current status of growth factors in the treatment of acute myeloid and lymphoblastic leukemia. Ottmann OG; Bug G; Krauter J Semin Hematol; 2007 Jul; 44(3):183-92. PubMed ID: 17631182 [TBL] [Abstract][Full Text] [Related]
40. Myeloid growth factors as anti-infective measures in children with leukemia and lymphoma. Lehrnbecher T; Creutzig U Expert Rev Hematol; 2009 Apr; 2(2):159-72. PubMed ID: 21083449 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]